Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Fusion Pharma, AstraZeneca Enter Radiopharmaceuticals Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Fusion Pharma, AstraZeneca Enter Radiopharmaceuticals Alliance

Leverages Fusion's Targeted Alpha Therapies platform and radiopharmaceuticals expertise and AstraZeneca's portfolio of antibodies and cancer therapies.

By: Contract Pharma

Contract Pharma Staff

Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on radiopharmaceuticals as precision medicines, has entered a collaboration with AstraZeneca to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer.

The collaboration leverages Fusion’s Targeted Alpha Therapies (TATs) platform and expertise in radiopharmaceuticals with AstraZeneca’s leading portfolio of antibodies and cancer therapeutics, including DNA Damage Response Inhibitors (DDRis).

The companies will work to discover, develop and commercialize novel TATs, which will utilize Fusion’s Fast-Clear linker technology platform with antibodies in AstraZeneca’s oncology portfolio. In addition, the companies will exclusively explore certain specified combination strategies between TATs (including Fusion’s lead candidate FPI-1434) and AstraZeneca therapeutics, for the treatment of various cancers. Both companies will retain full rights to their respective assets.

The agreement includes an upfront payment from AstraZeneca, as well as future development milestone and other payments.

Fusion will be responsible for preclinical development through first-time-in-human studies, while AstraZeneca will be responsible for clinical development. For these novel TATs, the companies will share development costs and Fusion will have co-promotion rights in the U.S. and AstraZeneca will have commercialization rights in the rest of the world. Both companies will have a 50/50 profit and loss share on a worldwide basis.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics